BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 27, Issue 5, Pages 644-650
Publisher
Springer Nature
Online
2013-10-25
DOI
10.1038/modpathol.2013.200
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome
- (2013) Christopher W. Toon et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
- (2013) V Eklöf et al. BRITISH JOURNAL OF CANCER
- Mutation-specific antibody detects mutant BRAFV600Eprotein expression in human colon carcinomas
- (2013) Frank A. Sinicrope et al. CANCER
- Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma
- (2013) Cheryl A Adackapara et al. HISTOPATHOLOGY
- BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer
- (2013) David Capper et al. INTERNATIONAL JOURNAL OF CANCER
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
- (2012) Reetesh K. Pai et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics
- (2012) A. I. Phipps et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis
- (2012) Matthew F. Kalady et al. DISEASES OF THE COLON & RECTUM
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803
- (2011) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
- (2010) A. Fariña-Sarasqueta et al. ANNALS OF ONCOLOGY
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- (2010) Inti Zlobec et al. INTERNATIONAL JOURNAL OF CANCER
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
- (2008) L. Barault et al. CANCER RESEARCH
- Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer
- (2008) A. J. French et al. CLINICAL CANCER RESEARCH
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
- (2008) S. Ogino et al. GUT
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started